References
- Centers for Disease Control and Prevention (CDC). Trends in tuberculosis incidence—United States, 2006. MMWR Morb Mortal Wkly Rep 2007:245–250.
- World economic forum annual meeting 2009 Davos-Klosters, Switzerland 28 January–1 February.
- Jain NK, Chopra KK., Prasad G. Multidrug -resistant initial and acquired isoniazid and rifampicin resistance to M. tuberculosis and its implications for treatment. Indian J Tuberc 1992;39:121–124.
- Goble M, Iseman MD, Medsen LA. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527–532.
- Park M, Davis AL, Schluger N, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983–1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996;153:317–324.
- Telzak EE, Sepkowitzk AP, Mannheimer S, Medard F. Successful treatment of multidrug-resistant tuberculosis (MDRTB) among HIV-negative patients. N Engl J Med 1995;333:907–911.
- Zignol M, Hosseini MS, Wright A. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479–485.
- Heifets LB, Flory MA, Lindholm-Levy P. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? J Antimicrob Agents Chemother 1989;33:1252–1254.
- Gundersen LL, Nissen-Meyer J, Spilsberg B. Synthesis and antimycobacterial activity of 6-arylpurines; the requirements for the N-9 substituent in active antimycobacterial purines. J Med Chem 2002;45:1383–1386.